Then again, so does fact that the company had already performed a and a reverse split in the past in order to stay liquid. Well, TCEL has not filed a financial report since the one covering Q1 2015. Its OTC Markets profile is stamped with a red warning sign which was definitely a glaring hint. There was no real way to know what one could expect from the company these days. However, if its last report is any indication, even if the company hadn’t been negligent in its filings, investors would probably not have been thrilled. Last time, it showed us some pretty miserable looking numbers: At TCEL Business Services, we understand that change, transition and relocation is not always easy. Since 2000, our founders have been helping companies and individuals respond to industry transitions in order to stay competitive. TCEL GROUP LTD is an active private limited company, incorporated on 22 October 2020. Our years of experience have taught us to always make your business or individual success our priority. The nature of the business is Management consultancy activities other than financial management. The companys registered office is on Covent Garden, London. The companys next accounts are due on 22 July 2022, and fall under the accounts category: No Accounts Filed. Not much going on there, one would be justified in thinking after reading said report on TCEL. How else could the company’s shares outstanding be 153 million on March 31, 2014, and then be 1.7 BILLION exactly one year later? For starters, there’s evidence of A LOT of dilution going on. The fact that so much stock has been issued at points in time when TCEL had been the target of paid pumps speaks volumes in and of itself. He is also currently a member of the International Society for the Biological Therapy of Cancer ( ISBTC).Then again, so does fact that the company had already performed a and a reverse split in the past in order to stay liquid.Īnd it looks like it is going to need another one pretty soon – because the way things are shaping up, it may find its way into FOUR ZERO TERRITORYbefore the session is over. Carl June where he became the director of the TCEL. From there, he joined The Translational Research Program under Dr. National Institutes of Health from 2003 – 2008 where he developed NY- ESO-1 TCR and Her2/Neu CAR transduced T cells into clinical trials. Next, he was a research fellow at the Surgery Branch of the National Cancer Institute at the U.S. For the next two years he was a research associate at Duke University Medical Center in Durham, North Carolina, where he worked on RNA transfected dendritic cell vaccines against tumors. ![]() He was a postdoctoral student and visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, from 1996 – 2000 where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. ![]() He is a graduate of the Third Medical University in Chongqing, China, where he received his PhD and MD. Yangbing Zhao is currently the Director of the TCEL at the Abramson Cancer Center and Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine.
0 Comments
Leave a Reply. |